title: Infliximab Modulates Cisplatin-Induced Hepatotoxicity in Rats.
abstract: BACKGROUND
  Cisplatin (Cis) is one of the most commonly used antineoplastic drugs. It is used as chemotherapy for many solid organ malignancies such as brain, neck, male and female urogenital, vesical and pulmonary cancers. Infliximab blocks tumor necrosis factor alpha (TNF-α). Several studies have reported that infliximab ameliorates cell damage by reducing cytokine levels.
  
  
  OBJECTIVE
  We aimed to investigate whether infliximab has a preventive effect against cisplatin-induced hepatotoxicity and whether it has a synergistic effect when combined with Cis.
  
  
  METHODS
  Animal experimentation.
  
  
  METHODS
  Male Wistar albino rats were divided in three groups as follows: Cis group, infliximab + Cis (CIN) group and the control group. Each group comprised 10 animals. Animals in the Cis group received an intraperitoneal single-dose injection of Cis (7 mg/kg). In the CIN group, a single dose of infliximab (7 mg/kg) was administered 72 h prior to the Cis injection. After 72 h, a single dose of Cis (7 mg/kg) was administered. All rats were sacrificed five days after Cis injection.
  
  
  RESULTS
  TNF-α levels in the Cis group were significantly higher (345.5±40.0 pg/mg protein) than those of the control (278.7±62.1 pg/mg protein, p=0.003) and CIN groups (239.0±64.2 pg/mg protein, p=0.013). The Cis group was found to have high carbonic anhydrase (CA)-II and low carbamoyl phosphate synthetase-1 (CPS-1) levels. Aspartate transaminase (AST) and alanine transaminase (ALT) levels were lower in the CIN group as compared to the Cis group. Total histological damage was greater in the Cis group as compared to the control and CIN groups.
  
  
  CONCLUSIONS
  Cis may lead to liver damage by increasing cytokine levels. It may increase oxidative stress-induced tissue damage by increasing carbonic anhydrase II (CA-II) enzyme levels and decreasing CPS-1 enzyme levels. Infliximab decreases Cis-induced hepatic damage by blocking TNF-α and it may also protect against liver damage by regulating CPS-1 and CA-II enzyme levels.
authors.affiliation: Department of Biochemistry, Recep Tayyip Erdoğan University School of Medicine, Rize, Turkey.
authors.forename: Medine Cumhur
authors.initials: MC
authors.lastname: Cüre
authors.affiliation: Department of Internal Medicine, Recep Tayyip Erdoğan University School of Medicine, Rize, Turkey.
authors.forename: Erkan
authors.initials: E
authors.lastname: Cüre
authors.affiliation: Department of Histology and Embryology, Recep Tayyip Erdoğan University School of Medicine, Rize, Turkey.
authors.forename: Yıldıray
authors.initials: Y
authors.lastname: Kalkan
authors.affiliation: Department of Biochemistry, Recep Tayyip Erdoğan University School of Medicine, Rize, Turkey.
authors.forename: Aynur
authors.initials: A
authors.lastname: Kırbaş
authors.affiliation: Department of Histology and Embryology, Recep Tayyip Erdoğan University School of Medicine, Rize, Turkey.
authors.forename: Levent
authors.initials: L
authors.lastname: Tümkaya
authors.affiliation: Department of Gastroenterology, Recep Tayyip Erdoğan University School of Medicine, Rize, Turkey.
authors.forename: Arif
authors.initials: A
authors.lastname: Yılmaz
authors.affiliation: Department of Physical Medicine and Rehabilitation, Recep Tayyip Erdoğan University School of Medicine, Rize, Turkey.
authors.forename: Ayşegül Küçükali
authors.initials: AK
authors.lastname: Türkyılmaz
authors.affiliation: Department of Pathology, Recep Tayyip Erdoğan University School of Medicine, Rize, Turkey.
authors.forename: İbrahim
authors.initials: İ
authors.lastname: Şehitoğlu
authors.affiliation: Department of Internal Medicine, Kumru State Hospital, Rize, Turkey.
authors.forename: Süleyman
authors.initials: S
authors.lastname: Yüce
keywords: Carbamoyl-phosphate synthetase 1; carbonic anhydrase; cisplatin; hepatotoxicity; infliximab; tumor necrosis factor alpha